{
    "id": "0847",
    "question": "A 37-year-old woman presents to your office with heartburn. Following an extensive workup, you diagnose her with a duodenal ulcer secondary to H. pylori infection. You prescribe triple therapy of omeprazole, clarithromycin, and amoxicillin. Which of the following best describes the mechanism of action of omeprazole?",
    "options": {
        "A": "Parasympathetic inhibition",
        "B": "Reversible block of H2 receptors",
        "C": "Inhibition of primary active transport",
        "D": "Inhibition of 50S ribosomal subunit"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to understand the mechanism of action of omeprazole, which is a proton pump inhibitor (PPI) used to treat duodenal ulcers caused by H. pylori infection.\\n\\nFirst, let's consider the options provided:\\n\\nA. Parasympathetic inhibition - This is not the mechanism of action of omeprazole. Parasympathetic inhibition is related to the parasympathetic nervous system, which is not directly related to the action of PPIs.\\n\\nB. Reversible block of H2 receptors - This is the mechanism of action of H2 receptor antagonists, not PPIs. H2 receptor antagonists block the action of histamine at H2 receptors in the stomach, reducing acid production.\\n\\nC. Inhibition of primary active transport - This is the mechanism of action of some antibiotics, but not PPIs. PPIs work by inhibiting the H+/K+ ATPase (proton pump) in the stomach, not primary active transport.\\n\\nD. Inhibition of 50S ribosomal subunit - This is the mechanism of action of macrolide antibiotics, such as clarithromycin, not PPIs. Macrolides inhibit protein synthesis by binding to the 50S ribosomal subunit.\\n\\nNow, let's consider the mechanism of action of omeprazole. Omeprazole is a PPI that works by inhibiting the H+/K+ ATPase (proton pump) in the stomach. This enzyme is responsible for pumping protons into the stomach lumen, and by inhibiting it, omeprazole reduces acid production in the stomach. This is an irreversible inhibition, meaning that once omeprazole binds to the H+/K+ ATPase, it cannot be easily removed from the enzyme.\\n\\nTherefore, the correct answer is C. Inhibition of primary active transport, but this is not the most accurate description. The more accurate description is that omeprazole inhibits the H+/K+ ATPase (proton pump) in the stomach, which is a type of primary active transport. However, this option is not available. The closest correct answer is C, but with the understanding that it is the inhibition of the proton pump, not primary active transport in the classical sense.\", \"answer_choice\": \"C\"}}",
    "snippets": [
        {
            "id": "Pediatrics_Nelson_2766",
            "title": "Pediatrics_Nelson",
            "content": "If H. pylori is present in association with ulcers, it should be treated with a multidrug regimen, such as omeprazole-clarithromycin-metronidazole, omeprazole-amoxicillin-clarithromycin, or omeprazole-amoxicillin-metronidazole, given twice daily for 1 to 2 weeks. Other proton-pump inhibitors may be substituted when necessary. Bismuth compounds are effective against H. pylori and can be considered. In North America, only the subsalicylate salt is available, the use of which raises some concerns about Reye syndrome and potential salicylate toxicity. Tetracycline is useful in adults, but should be avoided in children less than 8 years of age. In the absence of H. pylori, esophagitis and peptic ulcer disease are treated with a pro-ton-pump inhibitor, which yields higher rates of healing than H2 receptor antagonists. Gastric and duodenal ulcers heal in 4 to 8 weeks in at least 80% of patients. Esophagitis requires 4 to 5 months of proton-pump inhibitor treatment for optimal healing."
        },
        {
            "id": "First_Aid_Step2_278",
            "title": "First_Aid_Step2",
            "content": "H. pylori infection can be detected by urease breath test, serum IgG antibodies (which indicate exposure, not current infection), H. pylori stool antigen, or endoscopic biopsy. \u25a0\u2193 intake of offending agents. Antacids, sucralfate, H2 blockers, and/or PPIs may help. Triple therapy (amoxicillin, clarithromycin, omeprazole) to treat H. pylori infection. Give prophylactic H2 blockers or PPIs to patients at risk for stress ulcers (e.g., ICU patients). This malignant tumor is the second most common cause of cancer-related death worldwide and is particularly common in Korea and Japan. Tumors are generally adenocarcinomas, which exhibit two morphologic types: Intestinal type: Thought to arise from intestinal metaplasia of gastric mucosal cells. Risk factors include a diet high in nitrites and salt and low in fresh vegetables (antioxidants), H. pylori colonization, and chronic gastritis. Diffuse type: Tends to be poorly differentiated and not associated with"
        },
        {
            "id": "InternalMed_Harrison_3050",
            "title": "InternalMed_Harrison",
            "content": "Upper endoscopy is recommended as the initial test in patients with unexplained dyspepsia who are >55 years old or who have alarm factors because of the purported elevated risks of malig nancy and ulcer in these groups. However, endoscopic findings in unexplained dyspepsia include erosive esophagitis in 13%, peptic ulcer in 8%, and gastric or esophageal malignancy in only 0.3%. Management of patients <55 years old without alarm factors depends on the local prevalence of H. pylori infection. In regions with low H. pylori prevalence (<10%), a 4-week trial of an acid- suppressing medication such as a proton pump inhibitor (PPI) is recommended. If this fails, a \u201ctest and treat\u201d approach is most commonly applied. H. pylori status is determined with urea breath testing, stool antigen measurement, or blood serology testing."
        },
        {
            "id": "First_Aid_Step2_282",
            "title": "First_Aid_Step2",
            "content": "If perforation is likely, emergent surgery is indicated. Pharmacologic: Involves protecting the mucosa, decreasing acid production, and eradicating H. pylori infection. Treat mild disease with antacids or with sucralfate, bismuth, and misoprostol (a prostaglandin analog) for mucosal protection. PPIs or H2 receptor antagonists may be used to \u2193 acid secretion. Patients with confirmed H. pylori infection should receive triple therapy (amoxicillin, clarithromycin, and omeprazole). Discontinue use of exacerbating agents. Patients with recurrent or severe disease may require chronic symptomatic therapy. Endoscopy and surgery: Patients with symptomatic gastric ulcers for > 2 months that are refractory to medical therapy should have either endoscopy or an upper GI series with barium to rule out gastric adenocarcinoma. Refractory cases may require a surgical procedure such as parietal cell vagotomy (the most selective and preferred surgical approach)."
        },
        {
            "id": "InternalMed_Harrison_12591",
            "title": "InternalMed_Harrison",
            "content": "Any remaining symptoms are not due to H. pylori FIGuRE 188-2 Algorithm for the management of Helicobacter pylori infection. *Note that either the urea breath test or the stool antigen test can be used in this algorithm. Occasionally, endoscopy and a biopsy-based test are used instead of either of these tests in follow-up after treatment. The main indication for these invasive tests is gastric ulceration; in this condition, as opposed to duodenal ulceration, it is important to check healing and to exclude underlying gastric adenocarcinoma. However, even in this situation, patients undergoing endoscopy may still be receiving proton pump inhibitor therapy, which precludes H. pylori testing. Thus a urea breath test or a stool antigen test is still required at a suitable interval after the end of therapy to determine whether treatment has been successful (see text). \u2020Some authorities use empirical third-line regimens, of which several have been described."
        },
        {
            "id": "Surgery_Schwartz_7432",
            "title": "Surgery_Schwartz",
            "content": "in peptic ulcer. And even in the presence of active H pylori infection, strong acid suppression usually heals peptic ulcer, an observa-tion consistent with the old dictum \u201cno acid, no ulcer.\u201d But suc-cessful helicobacter treatment eliminates ulcer recurrence and the need for long-term PPI. And long-term PPI in patients with active Helicobacter infection may lead to corpus predominant gastritis, which leads to atrophic gastritis and increases the risk of gastric cancer. Thus, Helicobacter infection should be treated and eradication confirmed.Testing for H pylori infection should be performed in patients with peptic ulcer, gastritis, significant dyspepsia, MALT lymphoma, and early gastric cancer.85 Noninvasive methods for diagnosis of H pylori infection include the urea breath test, serology, and detection of stool antigen. The urea breath test has a sensitivity and specificity of greater than 90% and is useful for initial diagnosis of infection and for follow-up after eradication"
        },
        {
            "id": "Surgery_Schwartz_7477",
            "title": "Surgery_Schwartz",
            "content": "or emergent) who is noncompliant with, intolerant of, or cannot afford medical treatment. Historically, HSV has not performed particularly well for type II (gastric and duodenal) and type III (prepyloric) gastric ulcer, perhaps because of hypergastrinemia caused by gastric outlet obstruction and persistent antral stasis. Figure 26-32. Pneumoperitoneum on upright chest X-ray in patient with perforated ulcer.Table 26-10Helicobacter pylori therapies (10\u201314 days)Clarithromycin triple therapy standard or double dose PPI twice a day clarithromycin 500 mg twice a day amoxicillin 1 g twice a day; or metronidazole 500 mg three times a dayMetronidazole triple therapy standard or double dose PPI twice a day metronidazole 500 mg twice a day amoxicillin 1 g twice a dayLevofloxacin triple therapy standard dose PPI twice a day amoxicillin 1 g twice a day levofloxacin 500 mg dailySequential therapy standard or double dose PPI (10\u201314 days) amoxicillin 1 g twice a day (5\u20137 days); then clarithromycin"
        },
        {
            "id": "Obstentrics_Williams_7440",
            "title": "Obstentrics_Williams",
            "content": "With active ulcers, a search for H pylori is undertaken. Diagnostic aids include the urea breath test, serological testing, or endoscopic biopsy. If any of these yield positive results, combination antimicrobial and proton-pump inhibitor therapy is indicated. Several efective oral treatment regimens do not include tetracycline and can be used during pregnancy. hese 14-day regimens include amoxicillin, 1000 mg twice daily plus clarithromycin, 250 to 500 mg twice daily, plus metronidazole, 500 mg twice daily given along with the proton-pump inhibitor omeprazole (Del Valle, 2015)."
        },
        {
            "id": "InternalMed_Harrison_22506",
            "title": "InternalMed_Harrison",
            "content": "Transmission of H. pylori occurs from person to person, following an oral-oral or fecal-oral route. The risk of H. pylori infection is declining in developing countries. The rate of infection in the United States has fallen by >50% when compared to 30 years ago. pathophysiology H. pylori infection is virtually always associated with a chronic active gastritis, but only 10\u201315% of infected individuals develop frank peptic ulceration. The basis for this difference is unknown, but is likely due to a combination of host and bacterial factors some of which are outlined below. Initial studies suggested that >90% of all DUs were associated with H. pylori, but H. pylori is present in only 30\u201360% of individuals with GUs and 50\u201370% of patients with DUs. The pathophysiology of ulcers not associated with H. pylori or NSAID ingestion (or the rare Zollinger-Ellison syndrome [ZES]) is becoming more relevant as the incidence of H. pylori is dropping, particularly in the Western world (see below)."
        },
        {
            "id": "InternalMed_Harrison_22573",
            "title": "InternalMed_Harrison",
            "content": "Failure of H. pylori eradication with triple therapy in a compliant patient is usually due to infection with a resistant organism. Quadruple therapy (Table 348-4), where clarithromycin is substituted for metronidazole (or vice versa), should be the next step. The combination of pantoprazole, amoxicillin, and rifabutin for 10 days has also been used successfully (86% cure rate) in patients infected with resistant strains. Additional regimens considered for second-line therapy include levofloxacin-based triple therapy (levofloxacin, amoxicillin, PPI) for 10 days and furazolidone-based triple therapy (furazolidone, amoxicillin, PPI) for 14 days. Unfortunately, there is no universally accepted treatment regimen recommended for patients who have failed two courses of antibiotics. If eradication is still not achieved in a compliant patient, then culture and sensitivity of the organism should be considered. Additional factors that may lower eradication rates include the patient\u2019s country of"
        },
        {
            "id": "Surgery_Schwartz_7429",
            "title": "Surgery_Schwartz",
            "content": "with duode-nal ulcers, and at least 70% of patients with gastric ulcers, have H pylori infection. It is clear from multiple randomized prospec-tive studies that curing H pylori infection dramatically alters the natural history of PUD, decreasing the recurrent ulcer rate from more than 75% in patients treated with a course of acid-suppressive therapy alone (in whom H pylori is not eradicated) to less than 20% in patients treated with a course of antibacterial therapy (Fig. 26-26).83In patients with duodenal ulcer caused by helicobacter, the associated antral gastritis leads to relative hypergastrinemia by depleting antral somatostatin, the primary inhibitor of antral gastrin release. H pylori infection is associated with decreased Brunicardi_Ch26_p1099-p1166.indd 111801/03/19 7:11 PM 1119STOMACHCHAPTER 26levels of somatostatin, decreased somatostatin messenger RNA production, and fewer somatostatin-producing D cells. The mechanism of decreased antral somatostatin synthesis and"
        },
        {
            "id": "InternalMed_Harrison_22538",
            "title": "InternalMed_Harrison",
            "content": "Diagnostic Evaluation In view of the poor predictive value of abdominal pain for the presence of a gastroduodenal ulcer and the multiple disease processes that can mimic this disease, the clinician is often confronted with having to establish the presence of an ulcer. Documentation of an ulcer requires either a radiographic (barium study) or an endoscopic procedure. However, a large percentage of patients with symptoms suggestive of an ulcer have NUD; testing for H. pylori and antibiotic therapy (see below) is appropriate for individuals who are otherwise healthy and <45 years of age, before embarking on a diagnostic evaluation (Chap. 54). FIGURE 348-10 Barium study demonstrating (A) a benign duodenal ulcer and (B) a benign gastric ulcer."
        },
        {
            "id": "Pharmacology_Katzung_6847",
            "title": "Pharmacology_Katzung",
            "content": "H pylori-associated ulcers\u2014For H pylori-associated ulcers, there are two therapeutic goals: to heal the ulcer and to eradicate the organism. The most effective regimens for H pylori eradication are combinations of two antibiotics and a PPI. PPIs promote eradication of H pylori through several mechanisms: direct antimicrobial properties (minor) and\u2014by raising intragastric pH\u2014lowering the minimal inhibitory concentrations of antibiotics against H pylori. Until recently, the most commonly recommended treatment regimen consisted of a 14-day regimen of \u201ctriple therapy\u201d: a PPI twice daily; clarithromycin, 500 mg twice daily; and either amoxicillin, 1 g twice daily, or metronidazole, 500 mg twice daily. Due to increasing treatment failures attributable to rising clarithromycin resistance, \u201cquadruple therapy\u201d is now recommended as first-line treatment for patients who likely have clarithromycin resistance due to prior exposure or to residence in regions with high clarithromycin resistance."
        },
        {
            "id": "Anatomy_Gray_866",
            "title": "Anatomy_Gray",
            "content": "Duodenal ulcers usually occur in the superior part of the duodenum and are much less common than they were 50 years ago. At first, there was no treatment and patients died from hemorrhage or peritonitis. As surgical techniques developed, patients with duodenal ulcers were subjected to extensive upper gastrointestinal surgery to prevent ulcer recurrence and for some patients the treatment was dangerous. As knowledge and understanding of the mechanisms for acid secretion in the stomach increased, drugs were developed to block acid stimulation and secretion indirectly (histamine H2-receptor antagonists) and these have significantly reduced the morbidity and mortality rates of this disease. Pharmacological therapy can now directly inhibit the cells of the stomach that produce acid with, for example, proton pump inhibitors. Patients are also screened for the bacteria Helicobacter pylori, which when eradicated (by antibiotic treatment) significantly reduces duodenal ulcer formation."
        },
        {
            "id": "InternalMed_Harrison_3054",
            "title": "InternalMed_Harrison",
            "content": "Drugs that reduce or neutralize gastric acid are often prescribed for GERD. Histamine H2 antagonists like cimetidine, ranitidine, famotidine, and nizatidine are useful in mild to moderate GERD. For severe symptoms or for many cases of erosive or ulcerative esophagitis, PPIs such as omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole, or dexlansoprazole are needed. These drugs inhibit gastric H+, K+-ATPase and are more potent than H2 antagonists. Up to one-third of GERD patients do not respond to standard PPI doses; one-third of these patients have nonacidic reflux, whereas 10% have persistent acid-related disease. Furthermore, heartburn typically responds better to PPI therapy than regurgitation or atypical GERD symptoms. Some individuals respond to doubling of the PPI dose or adding an H2 antagonist at bedtime. Infrequent complications of long-term PPI therapy include infection, diarrhea (from Clostridium difficile infection or microscopic colitis), small-intestinal"
        },
        {
            "id": "InternalMed_Harrison_12576",
            "title": "InternalMed_Harrison",
            "content": "Primary phenomenon: Secondary phenomenon: Clinical outcome: Association with H. pylori (OR): Essentially all H. pylori\u2013colonized persons have histologic gastritis, but only ~10\u201315% develop associated illnesses such as peptic ulceration, gastric adenocarcinoma, or gastric lymphoma (Fig. 188-1). Rates among women are less than half of those among men for both diseases. Peptic ulcer Disease Worldwide, >80% of duodenal ulcers and >60% of gastric ulcers are related to H. pylori colonization (Chap. 348). However, in particular, the proportion of gastric ulcers caused by aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) is increasing, and in many developed countries these drugs have overtaken H. pylori as a cause of gastric ulceration. The main lines of evidence supporting an ulcer-promoting role for H. pylori are that the presence of the organism is a risk factor for the development of ulcers, (2) non-NSAID-induced ulcers rarely develop in the absence of H."
        },
        {
            "id": "InternalMed_Harrison_22591",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 348-12 Overview of new-onset dyspepsia. GERD, gastroesophageal reflux disease; Hp, Helicobacter pylori; IBS, irritable bowel syndrome; UBT, urea breath test. (Adapted from BS Anand and DY Graham: Endoscopy 31:215, 1999.) successful eradication. Some recommend that patients with complicated ulcer disease, or who are frail, should be treated with longterm acid suppression, thus making documentation of H. pylori eradication a moot point. In view of this discrepancy in practice, it would be best to discuss with the patient the different options available."
        },
        {
            "id": "Pediatrics_Nelson_2761",
            "title": "Pediatrics_Nelson",
            "content": "Acid-related injury can occur in the esophagus, stomach, or duodenum. Table 128-2 lists risk factors for peptic ulcer disease in children. Helicobacter pylori is responsible for more thanhalf of ulcers in the stomach and duodenum in adults. H. pyloriplays a significant but lesser role in childhood ulcer disease. Riskfactors for acquisition of H. pylori are low socioeconomic status and poor sanitation, with the highest incidence in developing countries. Nonulcer dyspepsia includes upper abdominalsymptoms (pain, bloating, nausea, early satiety) in the absenceof gastric or duodenal ulceration. Nonulcer dyspepsia is not associated with H. pylori infection. GER (see Chapter 128) allows acidic gastric contents to injure the esophagus, resultingin esophagitis. Esophagitis is characterized by retrosternal andepigastric burning pain and is best diagnosed by endoscopy. Itcan range from minimal, with only erythema and microscopicinflammation on biopsy, to superficial erosions and finally tofrank"
        },
        {
            "id": "Surgery_Schwartz_7442",
            "title": "Surgery_Schwartz",
            "content": "for the peptic ulcer complications of bleeding and perforation.93 This may be due in part to the increasingly com-mon use of NSAIDs and aspirin in this elderly cohort, many of whom also have H pylori infection.Pathophysiology and EtiologyA variety of factors may contribute to the development of PUD. Although it is now recognized that the large majority of duode-nal and gastric ulcers are caused by H pylori infection (see previ-ous discussion on H pylori) and/or NSAID use20,94 (Fig. 26-28), the final common pathway to ulcer formation is acid-peptic injury of the gastroduodenal mucosal barrier. Acid suppression heals both duodenal and gastric ulcers and prevents recurrence if continued. In general, H pylori predisposes to ulceration, both by acid hypersecretion and by compromise of mucosal defense mechanisms. NSAID use causes ulcers predominantly by com-promise of mucosal defenses. Duodenal ulcer was traditionally viewed as a disease of increased acid-peptic action on the duo-denal"
        },
        {
            "id": "Surgery_Schwartz_7459",
            "title": "Surgery_Schwartz",
            "content": "GI bleeding. Abdominal pain is quite uncommon. Shock may be present, necessitating aggressive resuscitation and blood transfusion. Table 26-7Patients taking NSAIDs or aspirin need concomitant acid suppressing medication if any of the following risk factors are present\u2022 Age over 60 years\u2022 History of acid/peptic disease\u2022 Concurrent steroid intake\u2022 Concurrent anticoagulant intake\u2022 High-dose or chronic NSAID use\u2022 High-dose or chronic aspirin use >325 mg/dayTable 26-8Indications for diagnosis and treatment of Helicobacter pyloriEstablished\u2022 Active peptic ulcer disease (gastric or duodenal ulcer)\u2022 Confirmed history of peptic ulcer disease (not previously treated for H pylori)\u2022 Gastric mucosa-associated lymphoid tissue lymphoma (low grade)\u2022 After endoscopic resection of early gastric cancer\u2022 Uninvestigated dyspepsia (depending on H pylori prevalence)Controversial\u2022 Nonulcer dyspepsia\u2022 Gastroesophageal reflux disease\u2022 Persons using NSAIDs\u2022 Unexplained iron deficiency anemia\u2022 Populations at"
        },
        {
            "id": "InternalMed_Harrison_22594",
            "title": "InternalMed_Harrison",
            "content": "ZES should be excluded with a fasting gastrin or secretin stimulation test (see below). More than 90% of refractory ulcers (either DUs or GUs) heal after 8 weeks of treatment with higher doses of PPI (omeprazole, 40 mg/d; lansoprazole 30\u201360 mg/d). This higher dose is also effective in maintaining remission. Surgical intervention may be a consideration at this point; however, other rare causes of refractory ulcers must be excluded before recommending surgery. Rare etiologies of refractory ulcers that may be diagnosed by gastric or duodenal biopsies include ischemia, Crohn\u2019s disease, amyloidosis, sarcoidosis, lymphoma, eosinophilic gastroenteritis, or infection (cytomegalovirus [CMV], tuberculosis, or syphilis)."
        },
        {
            "id": "InternalMed_Harrison_12581",
            "title": "InternalMed_Harrison",
            "content": "Functional Dyspepsia Many patients have upper gastrointestinal symptoms but have normal results on upper gastrointestinal endoscopy (so-called functional or nonulcer dyspepsia; Chap. 348). Because H. pylori is common, some of these patients will be colonized with the organism. H. pylori eradication leads to symptom resolution a little more commonly (from 0 to 7% in different studies) than does placebo treatment. Whether such patients have peptic ulcers in remission at the time of endoscopy or whether a small subgroup of patients with \u201ctrue\u201d functional dyspepsia respond to H. pylori treatment is unclear."
        },
        {
            "id": "Pathology_Robbins_3623",
            "title": "Pathology_Robbins",
            "content": "The discovery of the association of H. pylori with peptic ulcer disease revolutionized the understanding of chronic gastritis. These spiral-shaped or curved bacilli are present in gastric biopsy specimens from almost all patients with duodenal ulcers and a majority of those with gastric ulcers or chronic gastritis. Acute H. pylori infection is subclinical in most cases; rather, it is the chronic gastritis that ultimately brings the afflicted person to medical attention. H. pylori infection most often presents as an antral gastritis with increased acid production. The increased acid production may give rise to peptic ulcer disease of the duodenum or stomach."
        },
        {
            "id": "InternalMed_Harrison_22588",
            "title": "InternalMed_Harrison",
            "content": "APPROACH AND THERAPY: SUMMARY Controversy continues regarding the best approach to the patient who presents with dyspepsia (Chap. 54). The discovery of H. pylori and its role in pathogenesis of ulcers has added a new variable to the equation. Previously, if a patient <50 years of age presented with dyspepsia and without alarming signs or symptoms suggestive of an ulcer complication or malignancy, an empirical therapeutic trial with acid suppression was commonly recommended. Although this approach is practiced by some today, an approach presently gaining approval for the treatment of patients with dyspepsia is outlined in Fig. 348-12. The referral to a gastroenterologist is for the potential need of endoscopy and subsequent evaluation and treatment if the endoscopy is negative."
        },
        {
            "id": "Surgery_Schwartz_7478",
            "title": "Surgery_Schwartz",
            "content": "dose PPI twice a day amoxicillin 1 g twice a day levofloxacin 500 mg dailySequential therapy standard or double dose PPI (10\u201314 days) amoxicillin 1 g twice a day (5\u20137 days); then clarithromycin 500 mg twice a day and metronidazole 500 mg twice a day (5\u20137 days)Bismuth quadruple therapy (commonly used when above regimens fail to eradicate H pylori) standard dose PPI twice a day bismuth subsalicylate 300 mg four times a day tetracycline 500 mg four times a day metronidazole 250 mg four times a dayPPI = proton pump inhibitor.Table 26-11Clinical results of surgery for duodenal ulcer PARIETAL CELL VAGOTOMYTRUNCAL VAGOTOMY AND PYLOROPLASTYTRUNCAL VAGOTOMY AND ANTRECTOMYOperative mortality rate (%)0<11Ulcer recurrence rate (%)5\u2013155\u201315<2Dumping (%) Mild<51010\u201315 Severe011\u20132Diarrhea (%) Mild<52520 Severe021\u20132Reproduced with permission from Mulholland MW, Debas HT: Chronic duodenal and gastric ulcer, Surg Clin North Am. 1987 Jun;67(3):489-507.Brunicardi_Ch26_p1099-p1166.indd 112701/03/19"
        },
        {
            "id": "InternalMed_Harrison_22567",
            "title": "InternalMed_Harrison",
            "content": "Suggested treatment regimens for H. pylori are outlined in Table 348-4. Choice of a particular regimen will be influenced by several factors, including efficacy, patient tolerance, existing antibiotic resistance, and cost of the drugs. The aim for initial eradication rates should be 85\u201390%. Dual therapy (PPI plus amoxicillin, PPI plus clarithromycin, ranitidine bismuth citrate [Tritec] plus clarithromycin) is not recommended in view of studies demonstrating eradication rates of <80\u201385%. The combination of bismuth, metronidazole, and tetracycline was the first triple regimen found effective against TABlE 348-4 REGimEnS RECommEnDED foR ERADiCATion of H. PYLORI infECTion aAlternative: use prepacked Helidac (see text). bAlternative: use prepacked Prevpac (see text). cUse either metronidazole or amoxicillin, not both."
        },
        {
            "id": "Surgery_Schwartz_7450",
            "title": "Surgery_Schwartz",
            "content": "in DUvary in frequencyNocturnal acid secretionpH inhibition of gastrin releaseGastric emptyingPentagastrin-stimulated MAODaytime acid secretionDuodenal acid loadDuodenal HCO3 secretionFigure 26-28. \u201cCauses\u201d of peptic ulcer disease. Z.E. = Zollinger-Ellison syndrome. (Data from Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infec-tion on the long-term recurrence of gas-tric or duodenal ulcer. A randomized, controlled study, Ann Intern Med. 1992 May 1;116(9):705-708.)Conditions associated with peptic ulcerNSAIDuseNone knownZ.E., otherH. pyloriinfectionNSAIDuseNone knownZ.E., otherH. pyloriinfectionDuodenalGastricBrunicardi_Ch26_p1099-p1166.indd 112201/03/19 7:12 PM 1123STOMACHCHAPTER 26The overall risk of significant serious adverse GI events in patients taking NSAIDs is more than three times that of con-trols (Table 26-6). This risk increases to five times in patients more than age 60 years old. In elderly patients taking NSAIDs, the likelihood that"
        },
        {
            "id": "InternalMed_Harrison_12592",
            "title": "InternalMed_Harrison",
            "content": "The most clear-cut indications for treatment are H. pylori\u2013related duodenal or gastric ulceration or low-grade gastric B-cell lymphoma. Whether or not the ulcers are currently active, H. pylori should be eradicated in patients with documented ulcer disease to prevent relapse (Fig. 188-2). Testing for H. pylori and treatment if the results are positive also have been advocated in uninvestigated simple dyspepsia, but only when the prevalence of H. pylori in the community is >20% are these measures more cost-effective than simply treating the dyspepsia with PPIs. Guidelines have recommended"
        },
        {
            "id": "Pharmacology_Katzung_2257",
            "title": "Pharmacology_Katzung",
            "content": "Anthony J. Trevor, PhD not overweight, and she takes no prescription drugs. She drinks decaffeinated coffee but only one cup in the morning; however, she drinks as many as six cans per day of diet cola. She drinks a glass of wine with her evening meal but does not like stronger spirits. What other aspects of this patient\u2019s history would you like to know? What therapeutic measures are appropriate for this patient? What drug, or drugs, (if any) would you prescribe? At her annual physical examination, a 53-year-old middle school teacher complains that she has been having difficulty falling asleep, and after falling asleep, she awakens several times during the night. These episodes now occur almost nightly and are interfering with her ability to teach. She has tried various over-the-counter sleep remedies, but they were of little help and she experienced \u201changover\u201d effects on the day following their use. Her general health is good, she is"
        },
        {
            "id": "Surgery_Schwartz_7431",
            "title": "Surgery_Schwartz",
            "content": "duodenal metaplasia allows H pylori to colonize the duodenal mucosa, and this is where the duodenal ulcer occurs. In fact, in patients with gastric metapla-sia of the duodenum, the risk of developing a duodenal ulcer increases 50-fold. When H pylori colonizes the duodenum, there is a significant decrease in acid-stimulated duodenal bicarbonate release. When H pylori infection is successfully treated, acid secretory physiology tends to normalize. Relapse of duodenal ulcer after eradication of H pylori may signal reinfection of the gastric mucosa by the organism.Many patients with antral dominant helicobacter gastritis never develop duodenal ulcer, and some patients with peptic ulcer do not have Helicobacter. This obviously suggests that there are other important pathogenetic factors involved in peptic ulcer. And even in the presence of active H pylori infection, strong acid suppression usually heals peptic ulcer, an observa-tion consistent with the old dictum \u201cno acid, no ulcer.\u201d But"
        },
        {
            "id": "First_Aid_Step1_431",
            "title": "First_Aid_Step1",
            "content": "Proton pump inhibitors Omeprazole, lansoprazole, esomeprazole, pantoprazole, dexlansoprazole. meCHanism Irreversibly inhibit H+/K+ ATPase in stomach parietal cells. CliniCal Use Peptic ulcer, gastritis, esophageal reflux, Zollinger-Ellison syndrome, component of therapy for H pylori, stress ulcer prophylaxis. aDVerse eFFeCts \u008f risk of C difficile infection, pneumonia, acute interstitial nephritis. Vitamin B12 malabsorption; \u0090 serum Mg2+ and \u2022 Ca2+ absorption (potentially leading to increased fracture risk in elderly). Antacids Can affect absorption, bioavailability, or urinary excretion of other drugs by altering gastric and urinary pH or by delaying gastric emptying. All can cause hypokalemia. Overuse can also cause the following problems: Bismuth, sucralfate meCHanism Bind to ulcer base, providing physical protection and allowing HCO3 secretion to reestablish pH gradient in the mucous layer. Sucralfate requires acidic environment, not given with PPIs/H2 blockers."
        },
        {
            "id": "InternalMed_Harrison_22571",
            "title": "InternalMed_Harrison",
            "content": "One important concern with treating patients who may not need therapy is the potential for development of antibiotic-resistant strains. The incidence and type of antibiotic-resistant H. pylori strains vary worldwide. Strains resistant to metronidazole, clarithromycin, amoxicillin, and tetracycline have been described, with the latter two being uncommon. Antibiotic-resistant strains are the most common cause for treatment failure in compliant patients. Unfortunately, in vitro resistance does not predict outcome in patients. Culture and sensitivity testing of H. pylori is not performed routinely. Although resistance to metronidazole has been found in as many as 30% of isolates in North America and 80% in developing countries, triple therapy is effective in eradicating the organism in >50% of patients infected with a resistant strain. Clarithromycin resistance is seen in 13% of individuals in the United States, with resistance to amoxicillin being <1% and resistance to both metronidazole"
        }
    ],
    "scores": [
        0.03330467534699049,
        0.030536522301228185,
        0.029012010108526387,
        0.027973958881592265,
        0.02768705898329782,
        0.027440314993299804,
        0.026887486189983607,
        0.026758096057461274,
        0.026175167571925437,
        0.02600717518195301,
        0.024078704990069262,
        0.02397900781871447,
        0.023817640860348356,
        0.02356096691809705,
        0.02317481738102911,
        0.022978130634539087,
        0.022790973678648654,
        0.021262803232703714,
        0.021075131181101714,
        0.020109864461597453,
        0.019643663577127372,
        0.01942735978880557,
        0.018828369905956113,
        0.018329427519250083,
        0.017653890824622535,
        0.01739656606913244,
        0.017058652729384435,
        0.017027417027417027,
        0.016533442645350824,
        0.016530054644808743,
        0.016216565447732267,
        0.016016016016016016
    ]
}